In Abivax's trial, placebo patients dropped out due to lack of efficacy, meaning they were monitored for less time than patients on the effective drug. This "adverse event capture" bias can falsely make the drug arm appear to have a higher rate of side effects, a subtle but critical data interpretation error.

With half its patients from Asia and only 13% from North America, the Destiny Breast 11 trial's results may not be fully generalizable to US patients. Differences in metabolism, healthcare systems, and side effect reporting across regions can impact outcomes, a key consideration when interpreting global trial data.

Despite strong efficacy data, the drug DV-Toripalimab scored lower than a competitor (2.5 vs 3.0). Experts attribute this confidence gap to its Phase 3 trial being conducted only in China, which raises generalizability concerns and reflects a lack of hands-on experience for Western physicians.

The debate over Summit's Ivanecimab lung cancer data from its China-based Harmony 6 trial shows the risk of assuming data is globally applicable. Differences in patient populations, such as smoking history in squamous cell carcinoma, can make clinical results from one region non-translatable to another, posing a major challenge for global drug developers.

The STARGLO trial (glofitamab-gemox) showed a strong survival benefit in Asia-Pacific patients but not in the small North American cohort. This geographic discrepancy, with only 9% of patients from the US, was a key reason the FDA did not approve the combination, while European agencies did.

The INDEPENDENCE trial's initial results were confounded by external factors in specific regions. In Mainland China, restricted transfusion practices and a blood shortage led to a 40% placebo response rate, significantly higher than the drug's response rate in that region. This demonstrates how logistical and healthcare system realities can be critical confounding variables in global clinical studies.

The FDA is requiring higher US patient enrollment in global trials to address concerns that results from predominantly non-US populations (e.g., Asia) may not be generalizable. This reflects worries about differences in prior standard-of-care treatments and potential pharmacogenomic variations affecting outcomes.

Experts believe the stark difference in complete response rates (5% vs 30%) between two major ADC trials is likely due to "noise"—variations in patient populations (e.g., more upper tract disease) and stricter central review criteria, rather than a fundamental difference in the therapies' effectiveness.

Nektar's initial poor trial results were heavily impacted by one patient missing their week 12 appointment, which coincided with a rare, outlier placebo response. This unlucky convergence suppressed the reported drug efficacy, creating a massive misperception of the drug's potential.